Incubation Time and Test of Cure of Chlamydia Trachomatis (Incure)
Objective was to understand the dynamics of Chlamydia trachomatis (Ct) detection by nucleic acid amplification testing (NAAT) after treatment and consequences for test-of-cure practice.
Chlamydia Trachomatis Infection
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Time to Cure Chlamydia Trachomatis: Prospective Cohort Study on Detection of Chlamydial RNA and DNA in Anorectal and Cervicovaginal Infections During 8 Weeks After Directly Observed Treatment With Azithromycin|
- Duration of detection of Chlamydial rRNA and DNA after treatment [ Time Frame: 0 to 52 days after treatment ] [ Designated as safety issue: No ]At 1,2,3,4,5,6,7,9,12,16,19,23,26,30,37,44, and 52 days post treatment chlamydial rRNA and DNA is measured. Outcomes are the times to rRNA and/or DNA negative test results.
self-taken cervicovaginal and snorectal swabs
|Study Start Date:||June 2009|
|Study Completion Date:||July 2011|
|chlamydia care as usual|
Prospective Cohort Study on Detection of Chlamydial ribosomal ribonucleic acid (rRNA) and deoxyribonucleic acid (DNA) in anorectal and cervicovaginal Chlamydia trachomatis (Ct) infections during 8 weeks after directly observed treatment with Azythromycin. The investigators systematically assessed presence of Ct plasmid DNA and rRNA through multiple time-sequential measurements following treatment with 1000mg Azythromycin. By convenience sampling at our outpatient sexually transmitted diseases (STD) clinic, 46 non-pregnant women and 6 men were included, contributing 45 cervicovaginal and 15 anorectal infections. Over a period of 8 weeks, patients provided a total of 1016 self-taken cervicovaginal and/or anorectal swabs (response: 94%). All patients were negative for Human immunodeficiency virus (HIV), gonorrhea and Lymphogranuloma venereum (LGV), tested in anorectal Ct. Usual care was applied by advising abstinence or safe sex for one week and by providing treatment for steady partners. Participants provided written informed consent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01448876
|Public Health Service South Limburg|
|Geleen, South Limburg, Netherlands, PO Box 2022, 6160 HA Geleen|